Among the four key genes, the expression levels of PD-L2 and CTLA4 were significantly upregulated in the low-risk group (Figures 10B–E), indicating that the risk signature might play a vital role in predicting the treatment response of HCC patients to ICIs. This evidence concerns the gene PDCD1LG2 and hepatocellular carcinoma.